Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10283082" target="_blank" >RIV/00216208:11110/14:10283082 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/14:00075662 RIV/00216208:11130/14:10283082 RIV/61989592:15110/14:33149134 RIV/00064203:_____/14:10283082 RIV/00064190:_____/14:#0000808

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.urolonc.2013.09.011" target="_blank" >http://dx.doi.org/10.1016/j.urolonc.2013.09.011</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.urolonc.2013.09.011" target="_blank" >10.1016/j.urolonc.2013.09.011</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines

Popis výsledku v původním jazyce

Objectives: The aim of this retrospective study was to analyze prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (TKIs) sunitinib or sorafenib after progression on cytokine therapy. Materials andmethods: A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed. Results: Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs <1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI <1 year, increased lactate dehydro

Název v anglickém jazyce

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines

Popis výsledku anglicky

Objectives: The aim of this retrospective study was to analyze prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (TKIs) sunitinib or sorafenib after progression on cytokine therapy. Materials andmethods: A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed. Results: Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs <1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI <1 year, increased lactate dehydro

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Urologic Oncology: Seminars and Original Investigations

ISSN

1078-1439

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

488-495

Kód UT WoS článku

000335422300017

EID výsledku v databázi Scopus

—